ATL 104

Drug Profile

ATL 104

Alternative Names: ATL104

Latest Information Update: 21 Feb 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alizyme
  • Class
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Stomatitis

Most Recent Events

  • 01 Jan 2010 No development reported - Phase-I/II for Stomatitis in Germany (PO)
  • 01 Jan 2010 No development reported - Phase-II for Stomatitis in United Kingdom (PO)
  • 31 Jul 2009 Suspended - Phase-I/II for Stomatitis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top